Aprea Therapeutics Reports $37.8M Cash and Runway Into Q1 2028

Aprea reported $37.8 million in cash and cash equivalents as of September 30, 2026. The APR-1051 Phase 1 trial has expanded to nine sites, with updated interim data scheduled for presentation November 20, 2026.